HOME / VTE-DVT / PE / OVERVIEW
Choose ELIQUIS® to help your patients with DVT / PE
ELIQUIS (apixaban) – an oral, direct factor Xa inhibitor - is indicated for:
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.1
- Prevention of Venous Thromboembolic Event (VTE) in adult patients who have undergone elective hip or knee replacement surgery.1
Robust clinical evidence for ELIQUIS in patients with DVT / PE
AMPLIFY Clinical Trial
ELIQUIS demonstrated comparable efficacy with a significant reduction in the risk of major bleeding vs. enoxaparin / warfarin in the treatment of DVT / PE2
AMPLIFY-EXT Clinical Trial
ELIQUIS significantly reduced the risk of recurrent VTE or all-cause death with no significant difference in the rates of major and major / CRNM bleeding vs. placebo for the prevention of recurrent DVT / PE3
Real-World Data
In AMPLIFY, ELIQUIS demonstrated comparable efficacy, with a superior major bleeding profile vs. Enoxaparin / warfarin; this is now complemented by RWD2,4
ELIQUIS (apixaban) is indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75 years, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class ≥II); treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults; and, prevention of VTE in adult patients who have undergone elective hip or knee replacement surgery.1
Footnotes:
CRNM = Clinically Relevant Non-Major DVT = Deep Vein Thrombosis PE = Pulmonary Embolism
References:
- ELIQUIS® (apixaban) Summary of Product Characteristics.
- Agnelli G et al. N Engl J Med 2013; 369: 799–808.
- Agnelli G et al. N Engl J Med 2013; 368: 699–708.
- Weycker D et al. Thromb Haemost 2018; 118: 1951–1961.
Date of Preparation: October 2025 | Job Description: 432-IE-2500026